Fei Jin Sheng formula and its effectiveness in treating advanced non-small cell lung cancer: An observational study
Zhen Yan,
Wen-Cang Gao,
Xiao-Xiao Wang,
Hong-Quan Xu,
Qian Li,
Jian-Xiang Chen,
De-Xiang Pang,
Tian Xie
Affiliations
Zhen Yan
First Clinical Medical Institute, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China; Department of Traditional Chinese Medicine, Integrated Chinese and Western Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, 310000, China
Wen-Cang Gao
Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, 310005, China
Xiao-Xiao Wang
Department of GCP, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210029, China
Hong-Quan Xu
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China
Qian Li
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China
Jian-Xiang Chen
School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China
De-Xiang Pang
Department of Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, 310005, China
Tian Xie
First Clinical Medical Institute, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang, 311121, China; Corresponding author. First Clinical Medical Institute, Nanjing University of Chinese Medicine, No.138 of Xianlin Dadao, Xixia District, Nanjing, 210023, China.
Objective: This study involved evaluating the efficacy of the Feijinsheng formula in the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC). Methods: We extracted the medical records of patients with advanced NSCLC undergoing treatment in the oncology department at the Second Affiliated Hospital of Zhejiang Chinese Medicine University from the medical record system. After applying inclusion and exclusion criteria, clinical data of 150 patients were collected. The patients were stratified into two groups based on their usage of the Feijinsheng formula, comprising 69 cases in the Exposed group and 81 cases in the Control group. A comparative analysis of the survival time difference between the two groups was conducted. Results: The data between the two groups exhibited similarity (p > 0.05). Following treatment, the Exposed group demonstrated a notably prolonged overall survival time compared to the Control group (p 0.05). Conclusion: The Feijinsheng formula extended the duration of survival of patients with advanced NSCLC.
